Drug Profile


Alternative Names: AL-4943A; Allelock; ALO 4943A; KW-4679; Opatanol; Pataday; Patanase; Patanol; Pazeo

Latest Information Update: 22 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kyowa Hakko
  • Developer Alcon; Kyowa Hakko Kirin
  • Class Antiallergics; Antihistamines; Dibenzoxepins; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Pruritus; Rhinitis; Seasonal allergic rhinitis; Urticaria
  • Discontinued Asthma

Most Recent Events

  • 01 Oct 2015 Alcon Research completes phase III trial in Allergic conjunctivitis in China (NCT02322216)
  • 30 Jan 2015 Registered for Allergic conjunctivitis in USA (Ophthalmic, 0.7%)
  • 30 Dec 2014 Alcon Research plans a phase III trial for Allergic conjunctivitis in China (NCT02322216)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top